Skip to main content

Search

Search the site:

News, Views, and Advocacy From the Oncology Nursing Society

News & Views

Advocacy

Stories

News & Views

Latest Articles
Clinical Practice
ONS News
ONS Leadership

Trending Topics

Treatments
Research
Safety
COVID-19
ONS Congress
Clinical practice

View All Topics

Advocacy

Latest Articles
Updates
Get Involved

Stories View All

View All

Zoom Through Video Job Interviews With These Tips for Applicants and Hiring Managers

nursing professional development

Zoom Through Video Job Interviews With These Tips for Applicants and Hiring Managers

January 22, 2021

The Case of Concurrent Therapy Concerns

Treatment side effects

The Case of Concurrent Therapy Concerns

December 18, 2020

In a World Where You Can Be Anything, Be Kind

In a World Where You Can Be Anything, Be Kind

December 11, 2020

Nursing Innovation Links Rural Facilities to Resources and Experts to Provide High-Quality Care Across the Country

Access to cancer care

Nursing Innovation Links Rural Facilities to Resources and Experts to Provide High-Quality Care Across the Country

December 04, 2020

Why All Oncology Nurses Should Be Environmentalists

Oncology nurse influence

Why All Oncology Nurses Should Be Environmentalists

November 27, 2020

Search

News & Views

Advocacy

Stories

Home

Author Content

COVID-19 Drug Reference Sheet: Bamlanivimab

On November 9, 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization for bamlanivimab, an unapproved agent, to treat mild to moderate cases of the COVID-19 coronavirus. EUAs are not FDA approvals; rather, they authorize use of an unapproved medication in an emergency setting. Bamlanivimab’s initial supply is limited, but the manufacturer announced increased production and distribution in early 2021.

November 20, 2020

Clinical practice

Oncology Drug Reference Sheet: Lurbinectedin

In June 2020, the U.S. Food and Drug Administration granted accelerated approval to lurbinectedin (Zepzelca^TM) for adults with metastatic small cell lung cancer (SCLC) whose disease has progressed on or after platinum-based chemotherapy. The approval adds a second choice for patients who experience treatment-resistant SCLC progression, who previously had only topotecan as an option.

October 20, 2020

U.S. Food and Drug Administration (FDA)

Oncology Drug Reference Sheet: Enfortumab Vedotin-Ejfv

Enfortumab vedotin-ejfv (Padcev™) was granted accelerated approval in December 2019 for adults with locally advanced or metastatic urothelial cancer who previously received an immune checkpoint inhibitor (PD-1 or PD-L1 inhibitor) and platinum-containing therapy.

A Perspective on COVID-19 for New and Student Nurses

COVID-19 coronavirus’s ripple effects extend so far beyond health and health care. Life in the United States doesn’t look the same as it did a few months ago. We’re all affected in some way, but senior nursing students have a distinct set of circumstances related to the pandemic.

Oncology Drug Reference Sheet: Tocilizumab

Tocilizumab was approved in August 2017 for the treatment of chimeric antigen receptor T cell–induced cytokine release syndrome. In March 2020, the U.S. Food and Drug Administration approved a randomized, double-blind, placebo-controlled, phase III clinical trial to assess the safety and efficacy of tocilizumab plus standard of care in patients hospitalized with severe COVID-19 pneumonia.

Clinical practice

Emotional Coping Strategies for COVID-19

The COVID-19 novel coronavirus pandemic is turning the world, inside and outside of the hospital, upside down. Not only are oncology nurses seeing high demands at work, but changes and restrictions are being instated at home as well.

Clinical practice

COVID-19 Fact Sheet and Implications for Patients With Cancer

COVID-19 is a novel coronavirus (a large family of viruses that can cause cold-like illnesses) first identified in Wuhan, China, in December 2019. It is a respiratory illness and can be spread from person to person, possibly through respiratory droplets during close contact. The first case of COVID-19 in the United States was reported on January 21, 2020.

Oncology Drug Reference Sheet: Niraparib

Niraparib was approved in October 2019 for patients with homologous recombination deficiency (HRD)-positive advanced ovarian, fallopian tube, or primary peritoneal cancer.

February 25, 2020

Oncology Drug Reference Sheet: Radium 223 Dichloride

Radium 223 dichloride (Xofigo^®) is an alpha particle-emitting radioactive therapeutic agent approved by the U.S. Food and Drug Administration in 2013 for castrate-resistant prostate cancer.

December 24, 2019

Oncology nurse scientist

Beta Data Browser Puts Precision Medicine Cohort at Researchers’ Fingertips

The future of cancer care is here: precision medicine has led to many of today’s newest cancer treatments and has made incredible progress since former President Barak Obama first announced the U.S. Precision Medicine Initiative (PMI) in 2015.

Oncology Drug Reference Sheet: Combination Trastuzumab and Hyaluronidase-Oysk

A new product that combines trastuzumab and hyaluronidase (Herceptin Hylecta™) received U.S. Food and Drug Administration approval in February 2019 for the treatment of HER2-overexpressing breast cancer. The approval was based on the results of two randomized trials: HannaH and SafeHER.

Which Ambulatory Infusion Pump Is Best for 5-FU?

Because of its long infusion time over 46–48 hours, 5-fluorouracil (5-FU) is usually administered with an ambulatory infusion pump in the outpatient setting. However, two types of pumps exist. On one side of the spectrum is the elastomeric pump: small, compact, but gets the job done. On the other is the electronic pump: bigger, flashy, with lots of bells and whistles (literally). Here are the advantages and disadvantages of each.

Study Finds Three Priority Steps to Improve Cancer Survivorship

Healthcare providers need to address three priority areas to improve outcomes for cancer survivors and support caregivers for patients with cancer, according to findings from an evidence review published in CA: A Cancer Journal for Clinicians.

January 23, 2019

Oncology Drug Reference Sheet: Lutetium Lu 177 Dotatate

Lutetium Lu 177 dototate (Lutathera^®) was approved in January 2018 by the U.S. Food and Drug Administration to treat a specific group of neuroendocrine tumors (NETs) in the gastrointestinal tract. NETs are rare, and the tumors produce hormone-like substances in response to signals from the nervous system.

January 23, 2019

Advanced practice nursing (APN)

What APRNs Need to Know About Right to Try

The Right-to-Try law, which has been in effect since May 2018, may have a misleading name, given that it doesn’t require drug manufacturers to grant access to experimental treatments that have passed phase I trials to any patient who seeks it. Rather, the law grants terminally ill patients the “right to ask” the drug company directly, but the request can be denied for several reasons (e.g., limited supply, expense).

October 16, 2018

Clinical practice guidelines

TNM Gets an Upgrade in Eighth Edition Staging Guidelines

Nearly a century ago, cancer staging was a simple categorization of disease as either local, regional, or distant. Then in the 1940s, a French surgeon developed the concept for a staging system that uses the size of the primary tumor (T), its lymphatic involvement (N), and the presence of metastases (M) to stage a patient’s cancer based on the anatomic extent of the disease at the time of diagnosis.

August 09, 2018

To discuss the information in this article with other oncology nurses, visit the ONS Communities.

To report a content error, inaccuracy, or typo, email pubONSVoice@ons.org.

Chelsea Backler MSN, APRN, AGCNS-BC, AOCNS®

News, Views, and Advocacy From the Oncology Nursing Society

Legal Notices

Contact Us

Conferences

Advertising

Newsroom

Sitemap

Oncology Nursing Foundation

© Copyright 2021 Oncology Nursing Society

Back to Top ▲